RayKnowChina Research Map
Shortlist

RecruitingGliomaPhase 1

Registered title, quoted from ClinicalTrials.gov

Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma

An open trial on glioma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteSanbo Brain Hospital首都医科大学三博脑科医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05717699, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 1 year to 18 years; sex: all

    Registered eligibility fields

  2. After surgical resection, biopsy, chemotherapy, or radiation therapy, tumor progression must be confirmed by MRI scan.

    Inclusion criterion 2

    Biopsy is performed prior to injection of Ad-TD-nsIL12 to confirm DIPG (frozen section-based).

    Inclusion criterion 3

  3. Other investigational medications within 30 days prior to viral treatment.

    Exclusion criterion 2

  4. Pre-enrollment patients LPS (patients aged ≥1 and <16 years) and KPS (patients aged ≥16 years) ≥ 50.

    Inclusion criterion 4

  5. Transaminases (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) or total bilirubin > 3 times the upper limit of normal.

    Exclusion criterion 8

    Neutrophils < 1x10\^9/L.

    Exclusion criterion 9

    Platelets ≤ 100x10\^9/L.

    Exclusion criterion 10

    Hemoglobin < 9g/dl.

    Exclusion criterion 11

  6. A negative pregnancy test in fertile women (women are considered of childbearing potential (WOCBP) after menarche, unless permanently infertile, including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).

    Inclusion criterion 7

    Pregnant or breast-feeding females.

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05717699, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Informed consent of the parents or patient.
  • After surgical resection, biopsy, chemotherapy, or radiation therapy, tumor progression must be confirmed by MRI scan.
  • Biopsy is performed prior to injection of Ad-TD-nsIL12 to confirm DIPG (frozen section-based).
  • Pre-enrollment patients LPS (patients aged ≥1 and <16 years) and KPS (patients aged ≥16 years) ≥ 50.
  • Patient must be, in the investigator opinion, able to comply with all the protocol procedures.
  • Age 1-18 years.
  • A negative pregnancy test in fertile women (women are considered of childbearing potential (WOCBP) after menarche, unless permanently infertile, including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).
  • Lesion considered by the investigator to be accessible for stereotactic biopsy.

Exclusion Criteria:

  • Serious infections or intercurrent conditions, including but not limited to severe renal failure, liver failure, heart failure, or bone marrow failure, which are not permitted for inclusion according to the investigator's criteria. Patients must be afebrile (<38℃) at the time of viral therapy.
  • Other investigational medications within 30 days prior to viral treatment.
  • Participants with immunodeficiency, autoimmune disease, or active hepatitis.
  • Any medical or psychological condition that might interfere with the patient's ability to participate if older than 16 years or parents ability when younger than 16, or give informed consent or would compromise the patient's ability to tolerate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism.
  • Tumor with multiple location.
  • Pregnant or breast-feeding females.
  • Severe bone marrow hypoplasia.
  • Transaminases (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) or total bilirubin > 3 times the upper limit of normal.
  • Neutrophils < 1x10\^9/L.
  • Platelets ≤ 100x10\^9/L.
  • Hemoglobin < 9g/dl.
  • Patients with Li-Fraumini syndrome or a known germline defect in the retinoblastoma gene or its associated pathways.
  • Administer any type of vaccine within 30 days prior to Ad-TD-nsIL12 administration.
  • Blood transfusions or drugs (such as G-CSF) within 28 days before viral treatment to treat pancytopenia or other hematological disorders.

Quoted from ClinicalTrials.gov, NCT05717699, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05717699, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05717699